Clinical trial NCT00440687 - References

Chronic Obstructive Pulmonary Disease — Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care

Citation(s)

•   Alsaeedi A, Sin DD, McAlister FA
  The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002 Jul;113(1):59-65. Review.
•   Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA
  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196-204.
•   Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK
  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 May 13;320(7245):1297-303.
•   Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group
  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003 Feb 8;361(9356):449-56. Erratum in: Lancet. 2003 May 10;361(9369):1660.
•   Davies L, Angus RM, Calverley PM
  Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999 Aug 7;354(9177):456-60.
•   Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA
  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 Oct;57(10):847-52. Erratum in: Thorax. 2008 Aug;63(8):753.
•   EuroQol Group
  EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208.
•   Herland K, Akselsen JP, Skjønsberg OH, Bjermer L
  How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med. 2005 Jan;99(1):11-9.
•   Jarad NA, Wedzicha JA, Burge PS, Calverley PM
  An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med. 1999 Mar;93(3):161-6.
•   Jones PW, Quirk FH, Baveystock CM, Littlejohns P
  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992 Jun;145(6):1321-7.
•   Jones PW, Willits LR, Burge PS, Calverley PM; Inhaled Steroids in Obstructive Lung Disease in Europe study investigators
  Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003 Jan;21(1):68-73.
•   Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group
  Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001 Aug 1;164(3):358-64.
•   McGuire A, Irwin DE, Fenn P, Gray A, Anderson P, Lovering A, MacGowan A
  The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health. 2001 Sep-Oct;4(5):370-5.
•   Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R; IMPAC Study Group
  Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004 May;59(5):387-95.
•   National Collaborating Centre for Chronic Conditions
  Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax. 2004 Feb;59 Suppl 1:1-232.
•   O'Brien A, Russo-Magno P, Karki A, Hiranniramol S, Hardin M, Kaszuba M, Sherman C, Rounds S
  Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med. 2001 Aug 1;164(3):365-71.
•   Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J
  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998 Mar 14;351(9105):773-80. Erratum in: Lancet 1998 Jun 27;351(9120):1968.
•   Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee
  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76. Review.
•   Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV
  Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999 Jun 24;340(25):1948-53.
•   Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA
  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 May;161(5):1608-13.
•   Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA
  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22.
•   Spencer S, Calverley PM, Burge PS, Jones PW
  Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004 May;23(5):698-702.
•   Tirimanna PR, van Schayck CP, den Otter JJ, van Weel C, van Herwaarden CL, van den Boom G, van Grunsven PM, van den Bosch WJ
  Prevalence of asthma and COPD in general practice in 1992: has it changed since 1977? Br J Gen Pract. 1996 May;46(406):277-81.
•   van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C
  Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002 Nov 15;166(10):1358-63. Epub 2002 Sep 5.
•   van Schayck CP, Levy ML, Stephenson P, Sheikh A
  The IPCRG Guidelines: developing guidelines for managing chronic respiratory diseases in primary care. Prim Care Respir J. 2006 Feb;15(1):1-4. Epub 2006 Jan 18.
•   Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K
  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999 May 29;353(9167):1819-23.
•   Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC; COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group
  Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005 Jun;60(6):480-7.

Phase 4 Withdrawal of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease in Primary Care: a Randomised Controlled Trial

Details for clinical trial NCT00440687